Akebia Therapeutics Income Statement (2013-2026) | AKBA

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	52.91M	48.76M	-152.07M	41.37M	43.31M	48.71M	55.78M	40.01M	56.38M	42.05M	56.20M	32.61M	43.65M	37.43M	46.50M	57.34M	62.47M	58.77M	57.62M	53.54M
Cost of Revenue (Quarter)	43.48M	15.94M	11.59M	23.11M	18.60M	29.27M	-12.44M	11.18M	8.27M	9.00M	18.66M	2.59M	17.05M	14.16M	47.40M	7.62M	9.92M	9.38M	12.54M	12.29M
Gross Profit (Quarter)	9.43M	32.81M	-163.66M	18.27M	24.71M	19.44M	68.22M	28.83M	48.10M	33.05M	37.53M	30.01M	26.60M	23.27M	-0.90M	49.71M	52.55M	49.38M	45.09M	41.25M
Operating items
Amortization - Intangibles (Quarter)	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M	9.01M
Depreciation & Amortization - Total (Quarter)							0.41M	0.40M	0.40M	0.40M	0.39M	0.36M	0.40M	0.36M	0.34M	0.31M	0.32M	0.32M	0.32M	0.33M
Research & Development (Quarter)	3.00M	40.47M	29.56M	43.83M	26.03M	28.03M	32.10M	19.69M	20.20M	13.33M	9.87M	9.73M	7.65M	8.49M	11.79M	9.75M	11.01M	14.94M	1.00M	14.81M
Selling, General & Administrative (Quarter)	41.65M	46.36M	44.80M	44.57M	32.24M	31.89M	29.91M	25.05M	27.04M	22.71M	25.44M	25.44M	26.92M	26.52M	27.68M	25.74M	26.55M	29.09M	26.09M	30.44M
Restructuring Costs (Quarter)					14.53M	0.18M	1.22M	0.11M	-0.09M	0.17M		0.06M
Other Operating Expenses (Quarter)	35.11M	0.87M	1.03M	0.45M				0.17M	-0.50M			0.35M				0.39M	0.58M	0.58M	26.23M	0.38M
Operating Expenses (Quarter)	79.76M	87.70M	75.39M	88.85M	73.69M	60.84M	64.08M	45.41M	48.09M	37.07M	36.16M	35.94M	35.33M	35.77M	40.44M	36.20M	38.46M	44.93M	53.64M	45.95M
Operating Income (Quarter)	-79.34M	-54.89M	-65.34M	-59.58M	34.08M	-50.41M	-4.87M	-25.60M	-9.00M	-13.04M	1.37M	-14.94M	-8.72M	-12.51M	-14.31M	13.51M	14.09M	4.45M	-8.55M	-4.70M
EBIT (Quarter)	-79.34M	-54.89M	-65.34M	-59.58M	34.08M	-50.41M	-4.87M	-25.60M	-9.00M	-13.04M	1.37M	-14.94M	-8.72M	-12.51M	-14.31M	13.51M	14.09M	4.45M	-8.55M	-4.70M
Non-operating items
Interest & Investment Income (Quarter)	-4.96M	-5.08M	-5.08M	-5.06M	-5.04M	-3.95M	-1.64M	-1.56M	-1.64M	-1.41M	-1.42M	-2.50M	-2.15M	-6.66M	-6.88M	-7.77M	-6.83M	-4.75M	-4.83M	-4.69M
Other Non Operating Income (Quarter)	1.26M		2.41M	1.13M	0.41M	1.17M	-3.62M	0.28M	-0.01M	-0.04M	0.89M	0.10M		-0.02M	-0.56M	0.21M	-0.03M	-0.01M	-0.17M	0.00M
Non Operating Income (Quarter)	1.26M	0.43M	0.56M	1.13M	0.41M	1.17M	0.43M	0.28M	-0.01M	-0.04M	0.66M	0.10M	-0.04M	-0.02M	0.06M	0.21M	-0.03M	-0.01M	-0.12M	0.00M
Net income details
EBT (Quarter)	-84.30M	-59.97M	-70.42M	-64.64M	29.04M	-54.36M	-6.50M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	1.16M	-11.23M	-8.93M
Tax Provisions (Quarter)																		0.61M	1.01M	0.13M
Profit After Tax (Quarter)	-83.04M	-59.54M	-69.86M	-63.51M	29.45M	-54.10M	-6.07M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M	-12.24M	-9.05M
Income from Continuing Operations (Quarter)	-84.30M	-59.97M	-70.42M	-64.64M	29.04M	-54.36M	-6.50M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M	-12.24M	-9.05M
Consolidated Net Income (Quarter)	-84.30M	-59.97M	-70.42M	-64.64M	29.04M	-54.36M	-6.50M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M	-12.24M	-9.05M
Income towards Parent Company (Quarter)	-84.30M	-59.97M	-70.42M	-64.64M	29.04M	-54.36M	-6.50M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M	-12.24M	-9.05M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-83.04M	-59.54M	-70.42M	-63.51M	29.45M	-54.10M	-6.50M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M	-12.24M	-9.05M
Additional items
EPS (Basic) (Quarter)	-0.51	-0.34	-0.40	-0.35	0.16	-0.29	-0.04	-0.15	-0.06	-0.08	0.00	-0.09	-0.04	-0.10	-0.11	0.03	0.00	0.00	-0.05	-0.03
EPS (Weighted Average and Diluted) (Quarter)	-0.51	-0.34	-0.40	-0.35	0.15	-0.29	-0.04	-0.15	-0.06	-0.08	0.00	-0.09	-0.04	-0.10	-0.11	0.03	0.00	0.00	-0.05	-0.03
Shares Outstanding (Weighted Average) (Quarter)	157.60M	163.05M	165.95M	179.60M	181.61M	182.38M	182.78M	184.77M	186.82M	186.64M	187.47M	204.96M	207.33M	210.35M	210.95M	235.50M	262.57M	264.79M	257.16M	267.05M
Shares Outstanding (Diluted Average) (Quarter)	161.33M	173.78M	165.95M	179.60M	181.61M	182.38M	182.78M	184.77M	186.82M	186.64M	187.47M	204.96M	209.71M	210.35M	210.95M	241.60M	271.10M	262.68M	257.16M	267.05M
EBITDA (Quarter)	-83.04M	-59.54M	-69.86M	-63.51M	29.45M	-54.10M	-6.07M	-26.88M	-11.17M	-14.49M	0.61M	-17.98M	-8.58M	-20.04M	-22.80M	6.11M	0.25M	0.54M	-12.24M	-9.05M
Tax Rate (Quarter)																		53.25%	-8.98%	-1.41%

Research Tools

Akebia Therapeutics Income Statement (2013-2026) | AKBA

Create an account

Sign In

Reset Password